3387 related items for PubMed ID: 17313557
41. Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease.
Brandwein JM, Callum J, Sutcliffe SB, Scott JG, Keating A.
Bone Marrow Transplant; 1990 Feb; 5(2):99-103. PubMed ID: 2310878
[Abstract] [Full Text] [Related]
42. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence.
Tarella C, Cuttica A, Vitolo U, Liberati M, Di Nicola M, Cortelazzo S, Rosato R, Rosanelli C, Di Renzo N, Musso M, Pavone E, Santini G, Pescarollo A, De Crescenzo A, Federico M, Gallamini A, Pregno P, Romano R, Coser P, Gallo E, Boccadoro M, Barbui T, Pileri A, Gianni AM, Levis A.
Cancer; 2003 Jun 01; 97(11):2748-59. PubMed ID: 12767087
[Abstract] [Full Text] [Related]
43. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, Paleologos N, Correa DD, Anderson ND, Caron D, Zelenetz A, Nimer SD, DeAngelis LM.
J Clin Oncol; 2003 Nov 15; 21(22):4151-6. PubMed ID: 14615443
[Abstract] [Full Text] [Related]
44. Salvage chemotherapy with dexamethasone, etoposide, ifosfamide and cisplatin (DVIP) for relapsing and refractory non-Hodgkin's lymphoma.
Lazar AD, Shpilberg O, Shaklai M, Bairey O.
Isr Med Assoc J; 2009 Jan 15; 11(1):16-22. PubMed ID: 19344007
[Abstract] [Full Text] [Related]
45. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
Chen CI, Roitman D, Tsang R, Stewart AK, Keating A, Crump M.
Bone Marrow Transplant; 2002 Dec 15; 30(12):885-91. PubMed ID: 12476281
[Abstract] [Full Text] [Related]
46. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
Hänel M, Kröger N, Sonnenberg S, Bornhäuser M, Krüger W, Kroschinsky F, Hänel A, Metzner B, Birkmann J, Schmid B, Hoffknecht MM, Fiedler F, Ehninger G, Zander AR.
Ann Hematol; 2002 Feb 15; 81(2):96-102. PubMed ID: 11907790
[Abstract] [Full Text] [Related]
47. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
Dawson LA, Saito NG, Ratanatharathorn V, Uberti JP, Adams PT, Ayash LJ, Reynolds CM, Silver SM, Schipper MJ, Lichter AS, Eisbruch A.
Int J Radiat Oncol Biol Phys; 2004 May 01; 59(1):208-18. PubMed ID: 15093918
[Abstract] [Full Text] [Related]
48. High-dose sequential (HDS) chemotherapy with blood and marrow cell autograft as salvage treatment in very poor prognosis, relapsed non-Hodgkin's lymphoma.
Caracciolo D, Gavarotti P, Aglietta M, Bondesan P, Falda M, Gallo E, Locatelli F, Novarino A, Paolino F, Sanavio F.
Bone Marrow Transplant; 1993 Dec 01; 12(6):621-5. PubMed ID: 7907906
[Abstract] [Full Text] [Related]
49. Efficacy and feasibility of IDEA therapy for refractory or relapsed non-Hodgkin's lymphoma.
Nishimori H, Fujii N, Maeda Y, Matsuoka K, Takenaka K, Shinagawa K, Ikeda K, Matsuo K, Harada M, Tanimoto M.
Anticancer Res; 2009 May 01; 29(5):1749-54. PubMed ID: 19443398
[Abstract] [Full Text] [Related]
50. Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma.
Rigacci L, Fabbri A, Puccini B, Chitarrelli I, Chiappella A, Vitolo U, Levis A, Lauria F, Bosi A.
Cancer; 2010 Oct 01; 116(19):4573-9. PubMed ID: 20572029
[Abstract] [Full Text] [Related]
51. European experience with ifosfamide in lymphomas.
von Kalle AK, Schaadt M, Diehl V.
Semin Oncol; 1989 Feb 01; 16(1 Suppl 3):73-7. PubMed ID: 2468184
[Abstract] [Full Text] [Related]
52. Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens.
Ardeshna KM, Kakouros N, Qian W, Powell MG, Saini N, D'Sa S, Mackinnon S, Hoskin PJ, Goldstone AH, Linch DC.
Br J Haematol; 2005 Aug 01; 130(3):363-72. PubMed ID: 16042685
[Abstract] [Full Text] [Related]
53. High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.
Wadhwa PD, Fu P, Koc ON, Cooper BW, Fox RM, Creger RJ, Bajor DL, Bedi T, Laughlin MJ, Payne J, Gerson SL, Lazarus HM.
Biol Blood Marrow Transplant; 2005 Jan 01; 11(1):13-22. PubMed ID: 15625540
[Abstract] [Full Text] [Related]
54. Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study.
Moreau P, Milpied N, Voillat L, Colombat P, Mahé B, Rapp MJ, Moreau A, Dupas B, Bulabois CE, Juge-Morineau N, Harousseau JL.
Bone Marrow Transplant; 1998 Jun 01; 21(12):1193-6. PubMed ID: 9674850
[Abstract] [Full Text] [Related]
55. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL.
N Engl J Med; 1995 Dec 07; 333(23):1540-5. PubMed ID: 7477169
[Abstract] [Full Text] [Related]
56. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
Mayer J, Vásová I, Korístek Z, Navrátil M, Klabusay M, Doubek M, Vorlícek J, Cernilová I, Vodvárka P, Petráková K.
Eur J Haematol Suppl; 2001 Jul 07; 64():21-7. PubMed ID: 11486396
[Abstract] [Full Text] [Related]
57. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma -- a retrospective evaluation.
Demirer T, Ayli M, Fen T, Ozcan M, Arat M, Buyukberber S, Arslan O, Gurman G, Akan H, Ilhan O.
Bone Marrow Transplant; 2004 Nov 07; 34(9):781-6. PubMed ID: 15354206
[Abstract] [Full Text] [Related]
58. Mitoxantrone, carboplatin, cytosine arabinoside, and methylprednisolone followed by autologous peripheral blood stem cell transplantation: a salvage regimen for patients with refractory or recurrent non-Hodgkin lymphoma.
Sorá F, Piccirillo N, Chiusolo P, Laurenti L, Marra R, Bartolozzi F, Leone G, Sica S.
Cancer; 2006 Feb 15; 106(4):859-66. PubMed ID: 16419074
[Abstract] [Full Text] [Related]
59. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma.
Weaver CH, Schwartzberg L, Rhinehart S, West J, Zhen B, West WH, Buckner CD.
Bone Marrow Transplant; 1998 Feb 15; 21(4):383-9. PubMed ID: 9509973
[Abstract] [Full Text] [Related]
60. A novel high-dose chemotherapy protocol with autologous hematopoietic rescue in patients with metastatic breast cancer or recurrent non-Hodgkin's lymphoma.
Fontelonga A, Kelly AJ, MacKintosh FR, Hall S, Monroe P, Wilson GS, Shaft D, Ruthven A, Ascensao JL.
Bone Marrow Transplant; 1997 May 15; 19(10):983-8. PubMed ID: 9169642
[Abstract] [Full Text] [Related]
Page: [Previous] [Next] [New Search]
